TG THERAPEUTICS, INC. Form 8-K November 14, 2014

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 11, 2014

TG Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware 001-32639 36-3898269

(State or Other Jurisdiction (Commission File Number) (IRS Employer Identification No.)

of Incorporation)

3 Columbus Circle, 15th Floor


New York, New York 10019

(Address of Principal Executive Offices)

(212) 554-4484

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:



Item Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;5.02. Compensatory Arrangements of Certain Officers.

(e) On November 11, 2014, the Board of Directors of TG Therapeutics, Inc. ("TG") approved an amendment (the "Amendment") to the Restricted Stock Subscription Agreement of Sean Power, TG's Chief Financial Officer, dated as of November 15, 2011 (the "Restricted Stock Agreement").

Pursuant to the Amendment, the repurchase option lapse schedule on page 2 of the Restricted Stock Agreement was amended by deleting "November 15, 2014" and inserting "March 31, 2015."

Except as modified by the Amendment and described above, the material terms of the Restricted Stock Agreement remain unchanged. The Restricted Stock Agreement was filed as Exhibit 10.33 to TG's Form 10-K for the fiscal year ended December 31, 2011, and is incorporated herein by reference.

Item 9.01 Financial Statements And Exhibits.

(d) Exhibits.

10.1 Amendment to Restricted Stock Subscription Agreement, dated November 15, 2014, by and between TG Therapeutics, Inc. and Sean A. Power.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TG Therapeutics, Inc. (Registrant)

Date: November 14, 2014 By: /s/ Michael S. Weiss Name: Michael S. Weiss Title: Chief Executive Officer

INDEX TO EXHIBITS

Exhibit Number

10.1 Amendment to Restricted Stock Subscription Agreement, dated November 15, 2014, by and between TG Therapeutics, Inc. and Sean A. Power.